Patty Murray Questions NIH Director on Clinical Trial Disruptions and Fetal Research Bans

Clinical Trial Disruptions Under Trump Administration

• 📌 Senator Murray highlighted that the Trump administration terminated or froze 5,478 NIH grants, impacting over 74,000 trial participants and specifically 383 active clinical trials, including 118 cancer trials.
• ⚠️ Patients in these trials are in a "race for time," and Murray sought a guarantee that NIH would not terminate grants in a "wide ranging, halfhazard way" again.
• 💡 NIH Director Dr. Bhattacharya stated that resources were made available to ensure continuity of care for patients and that many disrupted trials were ultimately restored, with a focus on advancing health over political agendas.

NIH Advisory Council and Grant Funding

• 🏛️ Senator Murray raised concerns about NIH's ability to fund research due to disruptions in its advisory council meetings, mandated by law for grant awards.
• ⏳ She noted that advisory council members have not been replaced at the end of their terms, and the Advisory Committee to the Director was completely disbanded, with many institutes set to lose voting members.
• 🚀 Dr. Bhattacharya assured that he has ordered the nomination of new members and is working to staff these committees quickly to avoid delays in funding.

Ban on Fetal Tissue Research

• 🔬 NIH issued a ban on fetal tissue research, which Senator Murray stated has halted irreplaceable research for conditions like Alzheimer's and Parkinson's, and impacted groundbreaking advances like the polio vaccine and IVF.
• 📊 Dr. Bhattacharya cited the availability of new alternatives, such as induced pluripotent stem cells, as a reason for the decline in the use of fetal tissue, suggesting it is "not necessary for science."
• ⚠️ Murray expressed concern that this ban, issued with little notice, appears to be a political decision and could significantly impact patients, requesting a complete list of affected projects.
• 📈 The ban on fetal tissue research and potential threats to human embryonic stem cell research could affect upwards of 600 NIH projects totaling $325 million.